Aktis Oncology appoints Glenn Gormley to board; two directors resign

Aktis Oncology, Inc.

Glenn Gormley, MD, PhD appointed independent director and co-chair of new Science and Technology Committee, effective April 15, 2026.
Gormley, 72, previously Global Head of R&D at Daiichi Sankyo; over 30 years biopharma leadership.
Received option for 37,866 shares vesting over three years; annual cash compensation $45,000 plus $15,000 for committee role.
Helen S. Kim and Oleg Nodelman resign from board effective May 20, 2026; not due to any disagreement.
Gormley joins as company advances clinical milestones in targeted radiopharmaceuticals.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.